Post-Translational Modifications of STING: A Potential Therapeutic Target

Jiaqi Kang1, Jie Wu2, Qinjie Liu1, Xiwen Wu1*, Yun Zhao2* and Jianan Ren1*

1 Research Institute of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China, 2 Department of General Surgery, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, China

Stimulator of interferon genes (STING) is an endoplasmic-reticulum resident protein, playing essential roles in immune responses against microbial infections. However, over-activation of STING is accompanied by excessive inflammation and results in various diseases, including autoimmune inflammatory diseases and cancers. Therefore, precise regulation of STING activities is critical for adequate immune protection while limiting abnormal tissue damage. Numerous mechanisms regulate STING to maintain homeostasis, including protein-protein interaction and molecular modification. Among these, post-translational modifications (PTMs) are key to accurately orchestrating the activation and degradation of STING by temporarily changing the structure of STING. In this review, we focus on the emerging roles of PTMs that regulate activation and inhibition of STING by temporarily changing the structure of STING. In this review, we focus on the emerging roles of PTMs that regulate activation and inhibition of STING, and provide insights into the roles of the PTMs of STING in disease pathogenesis and as potential targeted therapy.

Keywords: STING, post translational modification, targeted therapy, diseases, phosphorylation

INTRODUCTION

Innate immunity is the front line of defense, protecting the host from microbial invasion and triggering adaptive immunity to eradicate infections. When pathogen-associated molecular patterns (PAMPs), including bacterial lipopolysaccharide (LPS) and viral nucleic acids, invade the body with or without tissue damage, pattern recognition receptors (PRRs), which are located on the cell membrane or in the cytoplasm, can be activated and mediate inflammatory and antiviral pathways to deal with infection (1, 2). In addition, tissue and cell damage are accompanied by damage-associated molecular patterns (DAMPs), such as abnormal DNA and cell organelle fragments, which can also be recognized by PRRs and induce cascades of inflammatory signaling pathways (2). PRRs are protein family including Toll-like receptors (TLRs), C-type lectin receptors (CLRs), NOD-like receptors (NLRs), retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), cyclic GMP-AMP synthase (cGAS), IFN-γ-inducible protein 16 (IFI16), absent in melanoma 2 (AIM2) and multiple DNA sensors (1–3). Different PRRs can be activated by different PAMPs, which then trigger innate immune responses to combat infection (1–4).

Specifically, cGAS, a protein that can enter and exit the nucleus, is recruited to abnormal DNA, which is classified into exogenous pathogenic DNA or endogenous instable heterotopic DNA, leading to a conformational change to bind to DNA (5–7). After that, AMP and GMP are catalyzed by cGAS,
releasing the second messenger 2′,3′-cyclic GMP-AMP (cGAMP), which functions as the second messenger to initiate adapter protein stimulator of interferon genes (STING) on the endoplasmic reticulum (ER) membrane (7, 8). STING then relocates to the Golgi apparatus, leading to production of cytokines, including type I interferon and other cytokines (7–10). Different immune cells can also produce various cytokines through cGAS–STING pathway to perform their respective function (11).

To date, STING has been generally considered to play a necessary role in immunity and inflammation. However, the regulatory mechanism of STING remains unclear. In addition to the direct interaction between cyclic dinucleotides and STING, post-translation modifications (PTMs) and protein-protein interactions could also alter STING function (4, 9, 12, 13). PTMs of proteins have been recognized as an important regulatory switch to temporally change the functions of proteins in cells. Most cellular proteins can be decorated by a diverse range of PTMs, including phosphorylation, acetylation, methylation, glutamylation, ADP-ribosylation, SUMOylation, and ubiquitination (14–17). In this review, we review the PTMs and function of STING signaling, highlighting the potential targeted therapy afforded by PTMs of STING.

AN OVERVIEW OF STING PATHWAY

STING, namely stimulator of interferon genes, also known as TMEM173, MITA, ERIS, and MPYS (18, 19), is a ~40-kDa transmembrane protein located on the ER membrane (20, 21). It is composed of a short N-terminal cytosolic segment, four transmembranes (TM) located in the ER membrane, a cytosolic ligand-binding domain (LBD), and a C-terminal tail (CTT) which is responsible for binding TBK1 (19, 21). It exists widely in nature, not only humans, but also chicken (22), shrimp (23), bacteria (24), and Drosophila (25), functioning as pathogen sensors to avoid infection.

As previously mentioned, cGAMP, catalyzed by cGAS, can alter the conformation of STING, resulting in the inward rotation of the two wings of STING toward each other. This process leads to closure of the ligand binding pocket and activation of STING (7). Then STING traffics in the form of COP-II vesicles from ER to ER-Golgi intermediate compartments (ERGIC) (26, 27). Some vesicles loaded with STING serve as a membrane source for modification by the ubiquitin-like protein LC3, which is a key step in autophagosome biogenesis (26). Most STING-coated ERGIC vesicles continue to traffic through the Golgi and post-Golgi endosomes. On the ERGIC membrane, STING recruits TBK1 (tanks binding kinase 1) and IKK (inhibitor of kappa B kinase), then TBK1 auto-phosphorylates and STING, IRF3 and IkBζ are phosphorylated (7, 27). Phosphorylated IRF3 dimerizes and translocates to activate transcription of type I IFN and interferon-stimulated genes (ISGs). Phosphorylation of IkBζ results in translocation of NF-kB to the nucleus, leading to transcription of genes encoding pro-inflammatory cytokines and chemokines such as IL-6 and TNF (28).

In addition, micronuclei (29), mtDNA (30), abnormal cell cycle (31), and cytoplasmic chromatin fragments (32) can activate STING through cGAS- dependent way. Several stimuli other than cGAMP, which is catalyzed by cGAS, for example, bacterial or virus cyclic dinucleotides (CDNs) (33, 34), can also activate STING directly. Apart from the production of type I interferon and cytokines, STING can also be associated with other biological and pathological process, such as ER stress (35), oxidative stress (36), fatty acid metabolism (37), Ca2+ homeostasis (38, 39), T cell proliferation (40), senescence (32) and so on. Moreover, STING can also participate in cell death pathways (41), including autophagy (30, 42), apoptosis (43), pyroptosis (44, 45), ferroptosis (46), necroptosis (47, 48), mitotic death (49), immunogenic cell death (ICD) (50). However, sometimes STING can help herpes virus assemble viral genome to host cell’s nucleus and survive in host cells, leading to severer virus infection at the early stage of infection (51).

Now that STING plays critical roles in biochemical processes, the expression and function of STING are tightly regulated. Apart from direct interaction between cGAMP and STING, protein-protein interaction and post-translational modification (PTMs) are also important (9, 12). Hundreds of proteins may interact with STING and affect its function (52). However, the regulation of STING in cells are basically dependent on the PTMs. In a word, PTMs are the key to regulating protein function and play a critical role in modulation of STING. Thus, we review PTMs of STING and prospect related targeted therapy.

MODIFICATION AND REGULATION OF STING

STING, a protein located in the ER, is composed of 379aa in human. Some residues of STING can be modified for its compartmentalization, dimerization, oligomerization, trafficking and degradation, which regulate immunological and other processes (Figure 1, 2). The consequence of PTMs is dependent on amino acid residue, type of modification group, thus biochemical process can be fully developed in cells. Therefore, we focus on different PTMs of STING and propose critical role of PTMs in activation or inhibition of STING. Modified residues and related proteins are shown in Figure 1. While Figure 2 shows how PTMs of STING affects STING pathway. Therefore, some PTMs in Figure 1 are not shown in Figure 2 due to the lack of literature.

Phosphorylation and Dephosphorylation

Phosphorylation is the most common PTMs in mammalian cells. It means the addition of phosphate groups to proteins, especially to amino acid residues, such as Ser and Thr (53). The addition or removal of phosphate groups (dephosphorylation) acts as a biological “on/off” in many reactions, including modulation of STING (9) (Figure 2).

It is confirmed that, oligomerized STING recruited TBK1, then TBK1 phosphorylated S366 of human STING (S365 in
mice), with the consequence of classic activation of STING pathway (54–56). CSK (C-terminal src kinase), another tyrosine kinase expressed broadly among mammalian cells, phosphorylates STING at Y240 and Y245 and activates immune responses via promoting aggregation of STING after HSV-1 infection (57). PPP6C, namely protein phosphatase 6 catalytic subunit, is a phosphatase. Knockdown of PPP6C greatly increased STING phosphorylation at S366 after dsDNA stimulation to enhance immune response (58). Y245 of STING can also be phosphorylated directly by EGFR (epidermal growth factor receptor) for STING trafficking to endosomes, thus type I-IFN are produced (59). SYK (spleen tyrosine kinase), another kinase, could also phosphorylate Y240 of STING and promote activation of STING (60).

However, to achieve cellular homeostasis, STING pathway can also be down-regulated via phosphorylation and dephosphorylation (Figure 2). For instance, STING is subsequently phosphorylated by UNC-51-like kinase (ULK1) at S366 so that sustained innate immune responses can be prevented (61). Dephosphorylation of S358 by Mg2+/Mn2+-dependent protein phosphatase 6 catalytic subunit, is a phosphatase. Knockdown of PPP6C greatly increased STING phosphorylation at S366 after dsDNA stimulation to enhance immune response (58). Y245 of STING can also be phosphorylated directly by EGFR (epidermal growth factor receptor) for STING trafficking to endosomes, thus type I-IFN are produced (59). SYK (spleen tyrosine kinase), another kinase, could also phosphorylate Y240 of STING and promote activation of STING (60).

In a word, phosphorylation and dephosphorylation of STING could be critical mechanism in development of diseases.

UBiqutylation and Deubiquitylation
UBiqutylation, a highly-conserved modification of protein, is the second most common PTM for proteins, after only phosphorylation (53). It can be divided into three types due to structural characteristics: mono-ubiquitination, poly-ubiquitination and branched ubiquitination (65). UBiqutylation (Ub) is initiated by a cascade of enzymatic reactions, which is catalyzed by Ub-activating (E1), Ub-conjugating (E2) and Ub-ligating (E3) enzymes (65). Firstly, ubiquitin (Ub) is activated by E1 in an ATP-dependent manner and then is transferred to E2. Then, specific E3 catalyzes the transfer of Ub from E2 to a specific substrate protein with the assistance of E1 (66). As a result, Ub is assembled covalently to the specific protein, especially to lysine residues, resulting in the regulation of quality and quantity of proteins through degradation in various physiological and/or pathological conditions.
Deubiquitylation happens along with ubiquitylation, and both of them together affect the maturation and degradation of proteins.

Specifically, STING can also be modified by Ub via E3 ubiquitin ligase (Figure 2). RNF115 (RING finger protein) can catalyze K63-linked polyubiquitination of STING at K224/20/289, promoting the translocation of STING from ER to Golgi (67). TRIM56 (tripartite motif protein) induces K63 linkage ubiquitination of STING at K150 due to stimulation of exogenous DNA, and promotes STING dimerization and recruitment of TBK1 (68). UBXN3B (ubiquitin regulatory X domain-containing proteins 3 b) facilitates TRIM56-dependent K63-linked ubiquitination of STING, thus leading to dimerization, trafficking, and activation STING signaling (69). MUL1 (mitochondrial E3 ubiquitin protein ligase 1) can catalyze K63-linked polyubiquitination of STING at K224 to help activation of STING signaling (70). TRIM32 targeted STING for K63-linked ubiquitination at K20/150/224/236 and promoted the STING pathway (71). However, HSV1 VP1/2 can deubiquitinate K63-linked polyubiquitination of STING, which is mediated by TRIM32, thus help HSV escape from immune responses and promote brain infections (72). Reverse transcriptase domain of HBV can also physically bind to STING to promote brain infections (73).

Deubiquitylation happens along with ubiquitylation, and both of them together affect the maturation and degradation of proteins. Specifically, STING can also be modified by Ub via E3 ubiquitin ligase (Figure 2). RNF115 (RING finger protein) can catalyze K63-linked polyubiquitination of STING at K224/20/289, promoting the translocation of STING from ER to Golgi (67). TRIM56 (tripartite motif protein) induces K63 linkage ubiquitination of STING at K150 due to stimulation of exogenous DNA, and promotes STING dimerization and recruitment of TBK1 (68). UBXN3B (ubiquitin regulatory X domain-containing proteins 3 b) facilitates TRIM56-dependent K63-linked ubiquitination of STING, thus leading to dimerization, trafficking, and activation STING signaling (69). MUL1 (mitochondrial E3 ubiquitin protein ligase 1) can catalyze K63-linked polyubiquitination of STING at K224 to help activation of STING (70). TRIM32 targeted STING for K63-linked ubiquitination at K20/150/224/236 and promoted the STING pathway (71). However, HSV1 VP1/2 can deubiquitinate K63-linked polyubiquitination of STING, which is mediated by TRIM32, thus help HSV escape from immune responses and promote brain infections (72). Reverse transcriptase domain of HBV can also physically bind to STING to promote brain infections (73).
STING and significantly reduces the K63-linked polyubiquitination of STING, protecting HBV from innate immune responses (73). These indicate that pathogen has developed PTMs targeted strategy to evade from host immune system. Autocrine motility factor receptor (AMFR) catalyzed the K27-linked polyubiquitination of STING in an insulin-induced gene 1 (INSIG1)-dependent manner, recruiting TANK-binding kinase 1 (TBK1) and facilitating its translocation to the perinuclear microsomes (74). Therefore, K63-linked and K-27 linked polyubiquitination play important roles in activation of STING pathway.

While RNF5 and RNF90 target STING at K150 for K48-linked ubiquitination and lead to degradation of STING after viral infection (75, 76). However, RNF26 promotes K11-linked polyubiquitination of STING at K150 and protects STING from RNF5-mediated K48-linked polyubiquitination and degradation, thus enhancing quick and efficient anti-viral responses (77). TRIM29 catalyzes K48-linked polyubiquitination at K288/337/370 and promotes the degradation of STING (78, 79). TRIM30α induces K48-linked ubiquitination of STING at K275 for proteasome-dependent degradation (80). There is another interesting protein, death-associated protein kinase 3 (DAPK3), which modifies STING ubiquitination differently in different situations. When cells are in basic condition, DAPK3 inhibited STING K48-linked poly-ubiquitination and proteasome-mediated degradation. By contrast, DAPK3 is required for STING K63-linked poly-ubiquitination and STING-TBK1 interaction after cGAMP stimulation (81). Recently, TRIM13 is discovered to bind to STING at resting state. After HSV-1 infection, K6-linked polyubiquitination at K19 is triggered by TRIM13, thus promoting degradation of STING (82). In a word, different types of ubiquitination precisely regulate activation or degradation of STING, including K11-linked, K27-linked, K48-linked, K63-linked, and K6-linked, leading to different effects in immune responses (69). K27-linked, K11-linked and K63-linked polyubiquitination can promote transport and activation of STING, while K6-linked, and K48-linked polyubiquitination mostly lead to degradation of STING (Figures 1, 2).

On the other hand, ubiquitin-specific protease (USP)21, a deubiquitinating enzyme, hydrolyzes K27/63-linked polyubiquitin chain on STING, resulting in negative regulation of STING and significant decrease of type I interferons (83). USP13 uncouples K27-linked polyubiquitin chains from STING and prevents the recruitment of TBK1 to inhibit STING pathway (84). USP35 directly removes K11-, K27-, K63-linked polyubiquitin of STING, thus inhibits phosphorylation and multimerization of STING to limit STING signaling (85). The MYSM1 (Myb-like, SWIRM, and MPN domains 1 protein), interacts with STING and cleaves STING K63-linked ubiquitination at K150 to inhibit cGAS-STING signaling (86). On the other hand, OTUD5 and USP20 catalyze the K48-linked deubiquitination of STING and inhibit STING degradation, thus maintain the stability of STING and promote activation of STING pathway (87–89). In conclusion, targeted ubiquitination could be potential therapeutic approach (Figures 1, 2).

**SUMOylation and deSUMOylation**

Small ubiquitin-related modifier (SUMO) is a widely expressed Ub-like protein, which is similar with Ub in structure and enzymatic cascade (16). There are three major SUMOs. SUMO-1 usually modifies a substrate as a monomer; while SUMO-2/3 can form poly-SUMO chains. Both SUMO-1 and poly-SUMO chains can interact with other proteins through SUMO-interactive motif (SIM) (16). Thus, SUMO modification participated mainly in enhancing protein-protein interaction and regulating proteins’ localization, stability and activity (16, 65). As for STING, TRIM38 mediates the SUMOylation of STING at K338 to inhibit STING degradation, promoting oligomerization of STING and recruitment of IRF3 (90). On the other hand, at the late stage of infection, STING is deSUMOylated by SUMO-specific protease (SENPs) after phosphorylation at S366, eventually leading to STING degradation and dampening innate immune responses (90) (Figures 1, 2). More studies are needed to figure out whether other SUMO-enzymes play roles in regulation of STING, for example, SAE1 (SUMO-activating enzyme subunit 1), a subunit of SUMO-activating enzyme, which might interact with STING and plays a role in regulation of STING (52).

**Palmitoylation**

Palmitoylation, or S-palmitoylation, a type of lipidation, can make proteins bind non-polar structures more tightly, with important function for the localization, diffusion, and physical interactions of these proteins within the cell. It is mainly related to palmitic acid (PA), which comes out either with intrinsic fatty acid synthesis, or fatty acid uptake from outside of cells (91). However, studies have also discovered that palmitoylation is not only associated with PA concentration, but also with the zinc finger DHHHC-type containing (ZDHHC) family of palmitoyl S-acyltransferases (PATs), ZDHHC3, ZDHHC7, ZDHHC15, which are mostly localized to the ER and Golgi apparatus (92, 93). On the other hand, depalmitoylation, which means the removal of S-palmitoylation, can be catalyzed by some depalmitoylases, which belong to the serine hydrolase family, including APT1 (LYPLA1), APT2 (LYPLA2) and so on (94).

It has been confirmed that the palmitoylation of cysteines 88 and 91 of STING participates in regulation of STING, but not trafficking of STING (95) (Figures 1, 2). Palmitoylation of STING triggers composition of a multimeric complex at the lipid rafts of the trans-Golgi network, which triggers STING interacting with TBK1 (96). Suppression of palmitoylation with 2-bromopalmitate (2-BP) and hydroxylamine eliminates the transcription of downstream inflammatory cytokine genes, thus the phenotype of STING-associated vasculopathy with onset in infancy (SAVI, an auto-inflammatory disease related to gain-of-function mutations of STING) could be improved. Mutation of C88/91 inhibits palmitoylation and decreases the activation of STING-dependent host defense genes (95). However, it is still unknown whether STING can be depalmitoylated by any of the depalmitoylases. More studies are needed to investigate functions of depalmitoylated STING and related mechanisms.
Nitro-Alkylation

Nitro-alkylation, which is related to nitro-fatty acids (NO2-FAs), has been discovered as potent inhibitors of STING signaling. NO2-FAs is a recently discovered group of bioactive lipids with anti-inflammatory and tissue protective functions (97). It is produced mainly in gastrointestinal tract during digestion. Meanwhile, it can come out locally to modify specific proteins through Michael addition reactions, so that inflammation responses can be regulated accurately (98).

As mentioned above, there are two cysteine residues in the N-terminal region of STING, Cys88/91, which can be recognized by NO2-FAs to covalently interact with, resulting in nitro-alkylation of STING (92). Once STING is nitro-alkylated by NO2-FAs, palmitoylation of STING is abolished and STING pathway is inhibited (92). In addition, treatment with nitro-fatty acids is sufficient to inhibit production of type I IFN in fibroblasts derived from SAVI patients (99). In conclusion, nitro-alkylation can be a potent inhibitor of palmitoylation in cells and disease (Figures 1, 2). However, there is still no enzymes covered which is responsible for alklylation of STING, or other proteins. In addition, studies have suggested that, prostaglandin reductase-1 (PtGR-1) promotes nitroalkane transition to inactive nitroalkanes, thus decreases alklyation of protein (100). However, it is still not clear, whether PtGR-1 affects regulation of STING, and how palmitoylation could be replaced or inhibited by alklylation under physiological conditions. More studies are needed to figure out deeper mechanisms.

Glycosylation

Glycosylation is one of the most diverse post-translational modifications in eukaryotic cells (101). Proteins are glycosylated by either enzymes or interaction directly with glucose (aldehyde form) through lysine and arginine residues in proteins, and eventually leading to advanced glycation end products so that participating in biological or pathological process (101). Glycosylation of proteins are complex, indicated by the diverse types of glycans, the multiple positions of glycans, various structures of glycoproteins and different glycosyltransferase enzymes, leading to various functions of proteins (102). Studies have discovered that, N41 of STING in mice could be a potential N-linked glycosylation site, however, no N-linked glycosylation was detected with deglycosylation experiments (43). Another experiment showed that, there are four putative N-glycosylation sites of STING in Drosophila, N84, N187, N270, N333. Among two forms of STING in drosophila (long form and short form), only long form of STING could be glycosylated thus promoting residence of STING on ER (103). However, the glycosylation of STING in human has not been studied well for unknown reasons.

Glycosaminoglycans (GAGs) are linear acidic polysaccharides, which can be divided into many groups (104). GAGs are subsequently modified by epimerization and sulfation to produce sulfated GAGs (sGAGs) (105). Researchers have discovered that sGAGs can interact with various proteins through their negatively charged sulfate groups (106). Studies have suggested that STING translocates to sGAG-containing vesicles after vaccinia virus infection and evolutionally-conserved bounds to sGAGs through its luminal, positively charged, and polar residues (Figures 1, 2). It is hypothesized that STING palmitoylation facilitates its clustering into lipid rafts on the Golgi apparatus from the STING cytosolic side, while sGAGs induce STING polymerization from the STING luminal side, and both of two methods together lead to full activation of STING and TBK1 (107). However, whether STING is glycosylated and regulated by other substances, especially glucose, are still unclear.

Carbonylation

Carbonylation, one of the most harmful irreversible oxidative protein modifications, is linked to lipid peroxidation. It is considered as a major hallmark of oxidative stress-related disorders, leading to biomolecule malfunctions and eventually cell death (108, 109). A large amount of evidence has indicated the role of carbonylated proteins in the initiation of inflammation and autoimmune responses (110). However, situation becomes different in STING. There are two carbonylation sites of STING, namely residues C88 and C257, which are conserved across species (111). It is confirmed that both HSV-1 infection and 4-hydroxynonenal (4-HNE, a type of lipid peroxidation metabolite) induce STING carbonylation through lipid peroxidation, preventing the palmitoylation and translocation of STING from the ER to the Golgi, with the consequence of down-regulating immune responses (Figure 2). While glutathione peroxidase 4 (GPX4) inhibits STING carbonylation and promote activation of STING. Although the critical carbonylation site of STING has been discovered, there are still many questions to be resolved: why does carbonylation of STING result in inhibition of inflammation, which is different from that of other proteins? Is there a deeper mechanism regulating inflammatory phenotype after carbonylation of proteins? Also, there are still doubts whether carbonylation could be a therapeutic target.

Reversible Oxidation and Others

Reversible oxidation is a type of reversible oxidative PTM, which is generally related to oxidation of cysteine (Cys), namely Cys ox-PTMs (112). Reversible Cys ox-PTMs consist of various patterns, including S-sulfenylataion (Cys-SOH), S-glutathionylation (Cys-SSG), and disulfide bond (113). The characteristics of this oxidation pattern are fast and reversible, contributing to quick transition of protein function, so that cells can adapt to a complicated environment. Studies have discovered that the reversible oxidation of C148 and C206 of STING in cells participate in the contradictory regulation of STING. C148 of STING is oxidized independent on CDN interaction in basic state. And this oxidation state of C148 makes for the binding of 2′,3′-cGAMP to STING (114). However, sequential oxidation of C206 of STING in response to 2′,3′-cGAMP leads to a conformational change which inhibits the phosphorylation of S366 and prevents-over-activation of STING (114). In addition, excessive ROS induced by viral infection can oxidize C148 and inhibit polymerization and activation of STING, thus helping virus evade from cellular defenses (115). However, it is still
unclear, whether other Cys of STING can be oxidized and play roles in regulation of STING. More researches are needed (Figures 1, 2).

It is suggested that disulfide bond is also a type of reversible oxidation, which mainly exists in secreted proteins. Disulfide bond is formed by Cys in the oxidizing environment of the cytosol and in the luminal part of proteins (lumen of mitochondria, ER, etc), with the consequence of a more stable structure of protein. There are five cysteines in the cytosolic domain of STING, only one of which (C148) are engaged in disulfide bonds (116). It is discovered that 2',3'-cGAMP induces closing of the human STING homo-dimer and leads to the formation of disulfide bond via C148. When C148 is mutated to alanine, the affinity of STING to cGAMP is weaker (116). However, more studies are needed to figure out, why disulfide bonds of STING can be produced in the cytosol, and whether disulfide bonds are associated with phase separation. Due to the important role of disulfide bond, it could be potential therapeutic target to improve STING-related auto-inflammatory diseases (Figures 1, 2).

There are still other PTMs which are important in biological and pathological processes, such as acetylation and deacetylation, methylation, biotinylation, ribosylation, carboxylation. However, there is still no evidence favoring these PTMs on STING. Therefore, more research and efforts should be taken into to discover more detailed regulatory mechanisms of STING. Understanding and exploring the underlying network of PTMs may provide new idea of targeted STING therapy.

PTM RELATED DISEASES AND TARGETED THERAPY

As mentioned above, PTMs play critical roles in stabilization, activation and inhibition of STING, thus the immune responses could be accurately regulated in biological and pathological processes (9) (Figure 2). The competition of different PTMs at the same residue is important for the regulation of STING activity and can be critical factor in development of diseases, including infectious diseases (117), cancer (118), auto-inflammatory diseases (116). Therefore, targeted STING therapies have been developed on the basis of PTMs. Since phosphorylation is the classic activation PTMs form of STING, almost all of the STING-related diseases are discovered to be associated with phosphorylation of STING. Therefore, we review as follows mainly those diseases, which are covered to be related to non-phosphorylation of STING. All of STING-related diseases are presented in Figure 3.

Infectious Diseases

Infection is caused by pathogens, including bacteria, virus, by which PAMPs can be produced, thus STING pathway can be activated to deal with infection (1). In most time, activation of STING can help to eliminate pathogens (4), while sometimes STING can also help pathogens survive in cells and evade from host immune surveillance (51, 119). Virus is unique, with the simple structure consisting of nucleic acid (DNA or RNA) and protein. Most studies about STING are developed in viral infection model, for example, HSV-1. On this basis, PTMs of STING are gradually discovered, especially carboxylation, ubiquitination, SUMOylation, deubiquitination, glycosylation (Table 1), and related strategies are implemented in virus vaccination (120). However, more studies are needed to figure out in which cases STING is beneficial for clearance of virus, and how we utilize STING in treatment of viral diseases (Table 1).

Bacterial infections are major infectious diseases worldwide, leading to many diseases, including pneumonia (121), tuberculosis (122), and sepsis (123). It is confirmed that, many gram-positive and negative bacterial (117) can release not only bacterial DNA, but also cyclic diadenosine monophosphate (c-di-AMP) and virulence factors, which can trigger cGAS-STING pathway and inflammatory responses. However, not all of STING activation is beneficial for the host. Activation of the cGAS-STING pathway can promote bacterial replication and intracellular bacterial survival after staphylococcus aureus and Brucella abortus infection (124, 125). Some important physiological or pathological processes such as blood coagulation and autophagy could also be influenced by cGAS-STING pathway after bacterial infection (117). When Listeria monocytogenes enters a cell, c-di-AMP can be secreted and promote activation of STING, resulting in the reduction of protective immune responses (126). Therefore, regulation and function of cGAS-STING pathway are complicated when pathogens invade. Studies about STING potential mechanism, apart from the mediator of immune responses, are still on the way.

Cancer

To date, tumorigenesis is regarded as a process driven by inflammation (127). Previously, it is favored that the formation of tumor is related to weakened surveillance of immune system. Therefore, as an activator of immune responses, activation of STING could be potential therapy of cancer (118, 128, 129).

Therapy of cGAMP or analogs into tumor-bearing mice results in substantial inhibition of tumor growth and improves the survival of the mice (130). As mentioned above, USP35 can directly deubiquitinate STING with K6/K11/K27/K29/K63-linked polyubiquitin chains and inhibit STING. Silencing USP35 potentiates cisplatin effects in ovarian cancer cells (85). Another kinase, DAPK3, is required for STING K63-linked polyubiquitination to activate STING pathway. However, DAPK3 loss-of-function has been discovered in several human tumor types (131), which could help tumor cells evade from host immunity and cancer immunotherapy. All of these encourage us that, cancer cells may develop anti-PTMs of STING strategy to avoid surveillance of host immune system, and targeted PTMs of STING could be potential therapy for cancer, especially those STING-sensitive cancers (Table 1).

Autoimmune and Inflammatory Disease

Mutation or abnormal activation of STING can lead to varieties of auto-immune and auto-inflammatory diseases, including systemic lupus erythematosus (SLE) and STING-associated
vasculopathy with onset in infancy (SAVI). SLE is a typical autoimmune disease, in which pathogenic auto-antibodies are produced, resulting in excessive inflammation and severe tissue damage (132). It remains controversial whether STING plays a necessary role in SLE (133). However, MYSM1 has been discovered as a suppressor of SLE, which actually triggers K63-linked deubiquitination of STING and inhibits STING pathway. Increased MYSM1 can decrease type I IFN, IL-6, and other inflammatory cytokines in SLE mice (86). This indicates us that targeted ubiquitination of STING therapy could help improve autoimmune and inflammatory diseases.

SAVI is an auto-inflammatory disease with the gain-of-function mutations of STING (V147L, V147M, N154S, V155M, C206Y, R281Q, R284G), characterized by early onset systemic inflammation, vasculopathy and interstitial lung disease (ILD) (134, 135). Studies have discovered that, mutants of STING in SAVI are accompanied by enhanced STING translocation, IRF3 phosphorylation, and IFN-β activity. Blocking C148-mediated disulfide bond can alleviate inflammatory responses in SAVI-modeled cells (116). In addition, treatment of NO₂-FAs, which can alkylate STING and inhibit palmitoylation, can decrease production of type I IFN in fibroblasts cultured from SAVI patients. Also, 2-BP can decrease type I IFN in SAVI-mutant HEK293T cells (99). All of these indicate that inhibition of palmitoylation and conformational change of STING, or promotion of nitro-alkylation could be potential target to treat SAVI, which reveal the importance of PTMs of STING in diseases.

**PTMs Targeted Therapy**

Considering the critical role of STING signaling pathway in inflammation and diseases, targeting STING may lead to novel therapeutics (27, 136). Many strategies are developed, including: production of STING, activation of STING, translocation and oligomerization of STING, degradation of STING and downstream signaling (137). Targeted these strategies develop agonists and inhibitors, some of which are related to PTMs (Table 2).

Agonists of STING have been developed for a long time. The most efficient agents are CDNs, which are fit to LBD of STING, resulting in rapid activation of STING pathway (137). Later, more agonists are reported and some of them have been applied.
TABLE 1 | PTMs of STING and associated study models.

| Diseases                      | Amino acid residues | PTMs                  | Related molecular   | Function                                    | References |
|-------------------------------|---------------------|-----------------------|---------------------|---------------------------------------------|------------|
| Viral infection               | S366                | phosphorylation       | TBK1                | activation                                  | Zhong B, et al. (54) |
|                               | Y240/Y245           | phosphorylation       | CSK                 | promoting binding of STING and cGAMP, activation | Gao P, et al. (57) |
|                               | Y245                | phosphorylation       | EGFR                | STING trafficking to endosomes, activation   | Wang C, et al. (59) |
|                               | Y240                | phosphorylation       | SYK                 | activation                                  | Wang C, et al. (60) |
|                               | S366                | phosphorylation       | ULK1                | inhibition                                  | Konno H, et al (61) |
|                               | S358                | dephosphorylation     | PPM1A               | inhibiting STING aggregation, inhibition    | Li Z, et al. (62) |
|                               | Y162                | dephosphorylation     | SHP1                | inhibition                                  | Wang Y, et al. (63) |
|                               | Y245                | dephosphorylation     | PPP6C               | inhibition                                  | Ni Q, et al. (65) |
|                               | C88/C257            | carboxylation         | GPX4                | inhibiting palmitoylation of STING, inhibition | Jia M, et al. (111) |
|                               | K224/20/289         | K63-linked ubiquitination | RNF115             | promoting aggregation of STING and recruitment of TBK1, activation | Zhang ZD, et al. (67) |
|                               | K150                | K63-linked ubiquitination | TRIM66              | promoting STING dimerization and recruitment of TBK1, activation | Tsuchida T, et al. (68) |
|                               | –                   | K63-linked ubiquitination | UBXN3B             | activation                                  | Yang L, et al. (69) |
|                               | K224                | K63-linked ubiquitination | MUL1                | activation                                  | Ni Q, et al. (70) |
|                               | K20/150/224/236     | K63-linked ubiquitination | TRIM32              | promoting recruitment and activation of TBK1, activation | Zhang J, et al. (71) |
|                               | K137/150/224/236    | K27-linked polyubiquitination | AMFR/INSIG1         | promoting recruitment of TBK1, activation   | Wang Q, et al. (74) |
|                               | K150                | K48-linked ubiquitination | RNF30               | enhancing the degradation of STING           | Yang B, et al. (76) |
|                               | K150                | K11-linked ubiquitination | RNF26               | protecting STING from RNFS-mediated degradation, activation | Qin Y, et al. (77) |
|                               | K288/K337/K370      | K48-linked ubiquitination | TRIM29              | promoting the degradation of STING           | Li Q, et al. (78) |
|                               | K275                | K48-linked ubiquitination | TRIM30a             | proteasome-dependent degradation, inhibition | Wang Y, et al. (79) |
|                               | K19                 | K6-linked ubiquitination | TRIM13              | promoting the degradation of STING           | Li X, et al. (62) |
|                               | K347                | K48-linked deubiquitination | OTUD5               | maintaining the stability of STING, activation | Guo Y, et al. (69) |
|                               | K338                | SUMOylation           | TRIM38              | maintaining the stability of STING, activation | Hu MM, et al. (90) |
|                               | –                   | K63/K27-linked deubiquitination | USP21               | inhibiting translocation of STING and recruitment of TBK1, inhibition | Chen Y, et al (83) |
|                               | –                   | K48-linked deubiquitination | USP20/USP18         | maintaining the stability of STING, activation | Zhang M, et al. (88) |
|                               | –                   | K27-linked deubiquitination | USP13               | preventing the recruitment of TBK1, inhibition | Sun H, et al. (84) |
|                               | K150                | K48-linked ubiquitination | RNFS                | promoting degradation of STING, inhibition  | Zhong B, et al. (75) |
|                               | Y46/H50/P110/Y106/S108 | glycosylation         | sGAGs               | promoting aggregation of STING, activation  | Fang R, et al. (107) |
|                               | C148                | oxidation             | ROS                 | Inhibiting polymerization and activation of STING, inhibition | Tao L, et al. (115) |
|                               | SAVI                | palmitoylation        | DHHC3/7/15          | promoting clustering of STING on TGNs, activation | Mukai K, et al. (95) |
|                               | C88/91              | nitro-alkylation       | NO2-FA              | inhibiting palmitoylation of STING, inhibition | Hansen A L., et al. (99) |
|                               | C148                | disulfide bond        | –                   | promoting the dimerization of STING, activation | Ergun S L., et al. (116) |
|                               | SLE                 | K63-linked deubiquitination | MYSM1               | blocking STING dimerization and aggregation and TBK1 and IRF3 recruitments, inhibition | Tian M, et al. (96) |
|                               | ovarian cancer      | –                     | K6/K11/K27/K29/K63-linked deubiquitination | USP35 inhibiting the binding of STING and TBK1, inhibition | Zhang J, et al. (85) |
into clinical trials to help with symptoms or enhance treatments, especially cancer (137). Novel STING agonist strategies include: bacterial vectors, CDNs, non-CDNs, nano vaccines, antibody-drug conjugate, exo-STING, etc. (160) (Table 3). In addition, other potential therapeutic agents have been explored in experiments in vivo or in vitro, such as CEP (156), KAS-08 (155), DW2282 (155), etc. These agents are mostly tightly related to phosphorylation of STING, which is considered as the marker of STING activation. It has been confirmed that diABZI (147), compound 53 (150), M04 (151), etc, regulate directly phosphorylation of STING (Table 2). While bisphenol A (BPA) can up-regulate ZDHHC1, a palmitoylase, indicating the underlying therapy of palmitoylation in regulation of STING (161). Therefore, PTMs play critical role in strategies of

| Inhibitors | Compound type | Compound name | Structural formula | Function | Disease | References |
|------------|---------------|---------------|--------------------|----------|---------|------------|
| vermiculine | LH519 | blocking phosphorylation of STING | – | Liu H, et al (155) |
| nitrofuran derivatives | C176 | decreasing expression of STING | acute lung injury | Wu B, et al (156) |
| | C178 | inhibiting the palmitoylation of STING | Trex1−/− | Haag, S. M. et al (96) |
| | H151 | inhibiting the palmitoylation of STING | Trex1−/− | Haag, S. M. et al (96) |
| NO2-FA | 9-NO2-OA | promoting nitro-alkylation and inhibiting the palmitoylation of STING | SAVI, viral infection | Hansen, A. L. et al (92), Hansen, A. L. et al (99) |
| | 10-NO2-OA | | | |
| | NO2-cLA | | | |
| | 2-BP | inhibiting the palmitoylation of STING | viral infection | Mukai K, et al (95) |
| | 4-HNE | inducing STING carbonylation and inhibiting the palmitoylation of STING | viral infection | Jia M, et al (111) |
| cyclopeptide | astin C | blocking the recruitment of IRF3 to STING | viral infection | Li S, et al (157) |

(Continued)
| Compound type            | Compound name | Structural formula | Function                              | Disease | References |
|--------------------------|---------------|--------------------|---------------------------------------|---------|------------|
| Benzodioxane Variants    | compound 18   | ![Structural formula](image) | inhibiting binding of 2'3'-cGAMP and STING | –       | Siu T, et al (145) |
| compounds containing a benzene-1-sulfonamido-3-amide group | SN-011 | ![Structural formula](image) | blocking CBD of STING and inhibiting oligomerization and phosphorylation of STING | Trex1-/- | Hong Z, et al (146) |
| ester alkaloids          | homoharringtonine (HHT) | ![Structural formula](image) | inhibiting interaction of STING and TBK1 | –       | Park G, et al (159) |
| flavonol                 | Kaempferol (KPF) | ![Structural formula](image) | blocking phosphorylation of STING | cisplatin-induced cardiac injury | Qi Y, et al (159) |
| amidobenzimidazole       | diABZI-4      | ![Structural formula](image) | inducing oligomerization of STING | viral infection | Humphries F, et al (160) |
|                          | compound 2    | ![Structural formula](image) | inducing phosphorylation of STING | colorectal tumours | Ramanjulu, J. M, et al (161) |
|                          | diABZI        | ![Structural formula](image) | inducing phosphorylation of STING | viral infection | Zhou Z, et al (141) |

(Continued)
TABLE 2 | Continued

| Inhibitors |
| --- |
| **Compound type** | **Compound name** | **Structural formula** | **Function** | **Disease** | **References** |
| --- | --- | --- | --- | --- | --- |
| 24b | 3,4-dihydroquinoxalin-2(1H)-one cyclic urea | | inducing phosphorylation of STING | colorectal tumours | Xi Q, et al (162) |
| compound92 | benzothiazinone | | inducing phosphorylation of STING | – | Basu S, et al (163) |
| compound53 | triazoloquinoxaline 1a | | inducing phosphorylation of STING | – | Hou H, et al (164) |
| M04 | 2-(cyclohexylsulfonyl)-N,N-dimethyl-4-tosylthiazol-5-amine | | inducing phosphorylation and trafficking of STING | viral infection | Abraham, J, et al (143) |
| CHX710 | 1H-benzimidazole-4-carboxamide derivatives | | activation of STING | – | Khiar, S, et al (165) |
| DW2282 | sulfonyleas | | inducing phosphorylation of STING | colorectal tumours | Jung, H. R., et al (140) |
| – | SINCRO | | promoting activation of STING | melanoma | Kimura, Y, et al (165) |
agonists. All of these agonists activate immune responses through cGAS-STING pathway, thus play a critical role in anti-cancer therapy.

As for inhibitors, strategies have also been developed to inhibit STING pathway: decreasing the expression of STING, blocking binding of 2’3’-cGAMP and LBD of STING, inhibiting phosphorylation, blocking traffic of STING, etc (27). Compound 18 is discovered to inhibit binding of 2’3’-cGAMP and STING, leading to inhibition of STING pathway (141). Other inhibitors are mainly associated with PTMs of STING. C176/C178/H151 have been discovered to inhibit palmitoylation of STING (96), while NO2-FAs result in nitro-alkylation to competitively inhibit palmitoylation (99). SN-011 can block phosphorylation of STING to decrease production of type I-IFN and inflammatory cytokines (142). Therefore, PTMs of STING can be important therapeutic target to regulate STING in inflammatory diseases. Targeted PTMs could be potential efficient strategy to improve related diseases.

In a word, many therapeutic targets related to STING are based on phosphorylation, palmitoylation (92), alkylation (99). There are few studies on agonists or inhibitors related to other PTMs, for example, ubiquitination, glycosylation, sumoylation, oxidation, carbonylation, which are also critical in regulation of STING. There have been developed many reviews about targeted therapy of ubiquitination (162–164), glycosylation (165), sumoylation (166), oxidation (167). More studies could focus on the role of these agonists and inhibitors in regulating STING pathway, proposing more comprehensive therapeutic strategies to improve STING-related diseases.

**SUMMARY AND FUTURE PERSPECTIVE**

Innate immune response is an important defender to deal with endogenous and exogenous abnormal situation in cells. As
mentioned above, STING pathway participates importantly in regulation of immune responses (4). Since the discovery of the cGAS-STING pathway, a series of biochemical, structural and genetic studies have been conducted and related mechanisms have been established. It is confirmed that, PTMs of STING are important in regulation of STING pathway (9). Many types of PTMs participate in regulation of activation or degradation of STING (12), including phosphorylation and dephosphorylation, palmitoylation, nitro-alkylation, glycosylation, ubiquitylation and deubiquitylation, SUMOylation, carbonylation, oxidation and so on, so that immune responses induced by STING could be activated or inhibited efficiently.

It is inspiring that the same amino acid residues of STING could be modified by different groups, resulting in distinct, even contrary consequences. For example, C88 could be palmitoylated to activate immune responses (92), while ROS and NO2-FA could result in carbonylation and alkylation of STING to inhibit production of type I IFNs (99, 111). Add or remove phosphorylated groups on Y245 and S366 can also function differently, which indicates the importance of PTMs to precisely regulate STING (56, 57, 61, 64).

Due to important role played by STING in immune responses and inflammation, the critical mechanism of PTMs of STING is deserved to explore and transform into potential therapeutic target. Since then, targeted therapy of STING has been highlighted in treatment of many diseases (27, 137). Most agonists have been explored to improve prognosis of cancer (168). Among them, the most common mechanism is to phosphorylate STING to activate immune responses. By contrast, nitrofuran derivatives, astin C and others are inhibitors of STING (96, 169), which could potentially help with auto-immune diseases and hyper-activation of inflammation. However, the potential mechanisms of those molecular agents are not clearly clarified, which limits wider

| AGENT | PHASE | TYPE OF CANCER | TIME | CLINICAL TRIAL NCT CODE |
|-------|-------|----------------|------|-------------------------|
| E-7766 | single agent | phase I | Advanced solid tumors or lymphomas, melanoma, head and neck squamous cell carcinoma (HNSCC), breast cancer, colorectal cancer, and/or other tumors including lymphomas | 2020.3-2022.12 | NCT04144140 |
| exoSTING (CDK-002) | single agent | phase II | Advanced/metastatic, recurrent, injectable solid tumors | 2020.9-2022.12 | NCT04592484 |
| IMSA-101 | single agent + Immune checkpoint inhibitor (ICI)/Immuno-oncology (IO) therapy | phase I/II | Advanced Treatment-Refactory Malignancies | 2019.9-2023.2 | NCT04020185 |
| ADU-S100 | Single agent + Ipilimumab | phase I | Advanced/Metastatic Solid Tumors or Lymphomas | 2016.4-2020.8 | NCT02675439 |
| +Pembrolizumab | phase II | Head and Neck Cancer | 2019.8-2021.6 | NCT03937141 |
| +PD-001 | phase I/II | Advanced/Metastatic Solid Tumors or Lymphomas | 2017.9-2020.12 | NCT03172936 |
| MK-1454 | Single agent + Pembrolizumab | phase I | Advanced/Metastatic Solid Tumors or Lymphomas | 2017.2-2022.10 | NCT03010176 |
| +Pembrolizumab | phase II | Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma | 2020.3-2023.4 | NCT04220866 |
| TAK-676 | +Radiation + Pembrolizumab | phase I | Non-small-cell Lung Cancer, Triple-negative Breast Cancer, or Squamous-cell Carcinoma of the Head and Neck | 2021.9-2024.1 | NCT04879849 |
| MK-1454 | Single agent + Pembrolizumab | phase I | Advanced/Metastatic Solid Tumors | 2020.7-2023.3 | NCT03010176 |
| SB-11286 | Single agent + Atezolizumab | phase I | Advanced Solid Tumors | 2019.9-2022.5 | NCT04096638 |
| SYN-STING | Single agent + Atezolizumab | phase I | Advanced/Metastatic Solid Tumors and Lymphoma | 2019.11-2023.6 | NCT04167137 |
| GSK-3745417 | Single agent + Pembrolizumab | phase I | refractory/relapsed solid tumors | 2019.3-2025.1 | NCT03843359 |
| BI-1387446 | Single agent + Pembrolizumab | phase I | Solid Tumors | 2020.3-2025.1 | NCT04147234 |
| SNK-281 | Single agent + Pembrolizumab | phase I | Advanced Solid Tumors and Lymphoma | 2020.11-2024.3 | NCT04096579 |
| BMS-986301 | Single agent + Nivolumab | phase I | Advanced Solid Cancers | 2019.3-2024.3 | NCT03966680 |
| TAK-500 | Single agent + Pembrolizumab | phase I | Select Locally Advanced or Metastatic Solid Tumors | 2022.1-2025.4 | NCT05070247 |
| MK-2118 | + Pembrolizumab | phase I | Advanced/Metastatic Solid Tumors or Lymphomas | 2017.9-2022.6 | NCT03249792 |
use of these drugs. In a word, due to complexity of immunity regulation, much remains to be learned about the regulation of STING and details of PTMs in STING pathway. Future therapeutic strategies could focus on optimizing PTMs on STING function in the right disease at the optimal time.

**AUTHOR CONTRIBUTIONS**

JK developed and wrote this review. JW and QL revised it critically for important intellectual content. XW, YZ, and JR provided approval for publication of the content. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate Immune Pattern Recognition: A Cell Biological Perspective. *Annu Rev Immunol* (2015) 33:257–90. doi: 10.1146/annurev-immunol-032414-122240
2. Gong T, Liu L, Jiang W, Zhou R. Damp-Sensing Receptors in Sterile Inflammation and Inflammatory Diseases. *Nat Rev Immunol* (2020) 20 (2):95–112. doi: 10.1038/s41577-019-0215-7
3. Zhuo G, Xu Y, Cen X, Nandakumar KS, Liu S, Cheng K. Targeting Pattern-Recognition Receptors to Discover New Small Molecule Immune Modulators. *Eur J Med Chem* (2018) 14482–92. doi: 10.1016/j.ejmech.2017.12.026
4. Li Z, Cai S, Sun Y, Li L, Ding S, Wang X. When Sting Meets Viruses: Sensing, Trafficking and Response. *Front Immunol* (2020) 11:2064. doi: 10.3389/fimmu.2020.02064
5. Zhang F, Yuan Y, Ma F. Function and Regulation of Nuclear DNA Sensors During Viral Infection and Tumorigenesis. *Front Immunol* (2020) 11:624556. doi: 10.3389/fimmu.2020.624556
6. Liu H, Zhang H, Wu X, Ma D, Wu J, Wang L, et al. Nuclear Cgas Suppresses DNA Repair and Promotes Tumorigenesis. *Nature* (2018) 563(7729):131–6. doi: 10.1038/s41586-018-0629-6
7. Hopfner KP, Hormung V. Molecular Mechanisms and Cellular Functions of Cgas-Sting Signalling. *Nat Rev Mol Cell Biol* (2020) 21(9):501–21. doi: 10.1038/s41580-020-0244-x
8. Yum S, Li M, Chen ZJ. Old Dogs, New Trick: Classic Cancer Therapies Activate Cgas. *Cell Res* (2020) 30(8):639–48. doi: 10.1042/s41422-020-0346-1
9. Wang Z, Chen N, Li Z, Xu G, Zhan X, Tang J, et al. The Cytosolic DNA-Sensing Cgas-Sting Pathway in Liver Diseases. *Front Cell Dev Biol* (2021) 9:717610. doi: 10.3389/fcell.2021.717610
10. Balka KR, De Nardo D. Nuclear and Spatial Mechanisms Governing Sting Signalling. *FEBS J* (2021) 288(19):5504–29. doi: 10.1111/febs.15640
11. Barrat FJ, Crow MK, Ivashkiv LB. Interferon Target-Gene Expression and Epigenomic Signatures in Health and Disease. *Nat Immunol* (2019) 20 (12):1574–83. doi: 10.1038/s41590-019-0466-2
12. Hong Z, Ma T, Liu X, Wang C. Cgas-Sting Pathway: Post-Translational Modifications and Functions in Sterile Inflammatory Diseases. *FEBS J* (2021). doi: 10.1111/febs.16137. Epub ahead of print.
13. Hu T, Pan M, Yin Y, Wang C, Cui Y, Wang Q. The Regulatory Network of Cyclic Gmp-Amp Synthase-Stimulator of Interferon Genes Pathway in Viral Evasion. *Front Microbiol* (2021) 12:790714. doi: 10.3389/fmicb.2021.790714
14. Song B, Liu D, Greco TM, Cristea IM. Post-Translational Modification Control of Viral DNA Sensors and Innate Immune Signaling. *Adv Virus Res* (2021) 109:163–99. doi: 10.1016/bs.avir.2021.03.001
15. Diskin C, Ryan TAJ, O’Neill LAJ. Modification of Proteins by Metabolites in Immunity. *Immunity* (2021) 54(1):19–31. doi: 10.1016/j.immuni.2020.09.014
16. Chang HM, Yeh EHT. Sumo: From Bench to Bedside. *Physiol Rev* (2020) 100 (4):1599–619. doi: 10.1152/physrev.00025.2019

**FUNDING**

The work was supported by National Natural Science Foundation of China (81772052, 82072149, 82072223, and 82100597), the Natural Science Foundation of Jiangsu Province (BK20201116, BK202010039), the program B for Outstanding PhD candidate of Nanjing University.

**ACKNOWLEDGMENTS**

The author wishes to thank Hanlu Hu of the Affiliated BenQ Hospital of Nanjing Medical University for chemical structure formula figures.
Specific DNA Damage in Breast Cancer. *J Natl Cancer Inst* (2017) 109(1): dwj199. doi: 10.1093/jnci/dwj199

32. Dou Z, Ghosh K, Vizioli MG, Zhu J, Sen P, Wangensteen KJ, et al. Cytoplasmic Chromatin Triggers Inflammation in Senescence and Cancer. *Nature* (2017) 550(7676):402–6. doi: 10.1038/nature24050

33. Ishikawa H, Ma Z, Barber GN. Sting Regulates Intracellular DNA-Mediated, Type I Interferon-Dependent Innate Immunity. *Nature* (2009) 461 (7265):788–92. doi: 10.1038/nature08476

34. Nandakumar R, Tschismarov R, Meissner F, Prabakaran T, Krissanaprasit K, et al. Intrinsic Antiproliferative Activity of the Innate Sensor Sting in T Cells. *Commun Biol* (2021) 4(1):820. doi: 10.1038/s42003-021-02310-y

35. Xiong R, Li N, Chen L, Wang W, Wang B, Jiang W, et al. Sting Protects Against Cardiac Dysfunction and Remodelling by Blocking Autophagy. *Signal Transduct Target Ther* (2022) 1885. doi: 10.1038/s41392-021-00613-4

36. Wu J, Liu Q, Zhang X, Wu X, Zhao Y, Ren J. Sting-Dependent Induction of Lipid Peroxidation Mediates Intestinal Ischemia-Reperfusion Injury. *Free Radic Biol Med* (2021) 163:135–40. doi: 10.1016/j.freeradbiomed.2020.12.010

37. Kanno T, Nakajima T, Yokoyama S, Assou HK, Sasamoto S, Kamii Y, et al. Scd2-Mediated Monoensaturated Fatty Acid Metabolism Regulates Csgas-Sting-Dependent Type I Ifn Responses in Cdg(-/-) T Cells. *Commun Biol* (2021) 4(1):820. doi: 10.1038/s42003-021-02310-y

38. Srikanth S, Woo JS, Wu B, El-Sherbiny YM, Leung J, Chupradit K, et al. The Ca(2+) Sensor Stim1 Regulates the Type I Interferon Response by Releasing the Signaling Adaptor Sting at the Endoplasmic Reticulum. *Nat Immunol* (2019) 20(2):152–62. doi: 10.1038/s41590-018-0287-8

39. Wu J, Chen YJ, Dobbs N, Sakai T, Liu J, Miner JJ, et al. Sting-Mediated Interferon Induction by Herpes Simplex Virus 1 Requires the Protein Tyrosine Kinase Syk. *Cell Death Dis* (2021) 6(1):208. doi: 10.1038/s41467-018-04759-8

40. Ni G, Ma Z, Wang L, Ketkar H, Ma J, Yang G, Cui S, et al. Ubxn3b Positively Regulates Sting-Dependent Innate Immune Responses. *mBio* (2020) 11(4):e01728-20. doi: 10.1128/mBio.01728-20

41. Zhang R, Kang R, Tang D. The Sting1 Network Regulates Autophagy and Cell Death. *Signal Transduct Target Ther* (2021) 6(1):208. doi: 10.1038/s41467-018-04759-8

42. Xu JW, Chen Y, Lim BJW, Gasser S, Crasta KC, Gan YH. Bacterial-Induced Cell Fusion Is a Danger Signal Triggering Csga-Sting Pathway Via Micronuclei Formation. *Proc Natl Acad Sci USA* (2020) 117(27):15923–34. doi: 10.1073/pnas.2006908117

43. Tang CH, Zundell JA, Ranatunga S, Lin C, Nefedova Y, Del Valle JR, et al. Sting-IRF3 Pathway Links Endoplasmic Reticulum Stress With Hepatocyte Apoptosis in Early Alcoholic Liver Disease. *Proc Natl Acad Sci USA* (2013) 110(41):16544–9. doi: 10.1073/pnas.1308331110

44. Petrasek J, Iraechta-Velvle A, Csak T, Satisfichandran A, Kody L, Kurt-Jones EA, et al. Sting-IRF3 Pathway Links Endoplasmic Reticulum Stress With Hepatocyte Apoptosis in Early Alcoholic Liver Disease. *Proc Natl Acad Sci USA* (2013) 110(41):16544–9. doi: 10.1073/pnas.1308331110

45. Wu J, Liu Q, Zhang X, Wu X, Zhao Y, Ren J. Sting-Dependent Induction of Lipid Peroxidation Mediates Intestinal Ischemia-Reperfusion Injury. *Free Radic Biol Med* (2021) 163:135–40. doi: 10.1016/j.freeradbiomed.2020.12.010

46. Li C, Liu J, Hou W, Kang R, Tang D. Sting1 Promotes Ferroptosis Through Enhancing Intestinal Epithelium Pyroptosis. *Front Cell Dev Biol* (2022) 10:572. doi: 10.3389/fcell.2021.698679

47. Dou Z, Ghosh K, Vizioli MG, Zhu J, Sen P, Wangensteen KJ, et al. Intrinsic Antiproliferative Activity of the Innate Sensor Sting in T Cells. *Commun Biol* (2021) 4(1):820. doi: 10.1038/s42003-021-02310-y

48. Zhang X, Wu J, Liu Q, Li X, Li S, Chen J, et al. Ppp6c Negatively Regulates Sting-Dependent Innate Immune Responses. *mBio* (2020) 11(4):e01728-20. doi: 10.1128/mBio.01728-20

49. Wang C, Xiang C, Lu X, Wang X, Wang L, Wang Y, et al. Intracellular Nucleic Acid Sensing Mimics the Type I Interferon-Dependent Innate Immunity. *Sci China Life Sci* (2018) 61(4):701–9. doi: 10.1007/s11427-015-0047-3

50. Chattopadhyay S, Liu YH, Fang ZS, Lin CL, Lin JC, Yao BY, et al. Synthetic Immunogenic Cell Death Mediated by Intracellular Delivery of Sting Agonol Nanobells Enhances Anticancer Chemotheranmunotherapy. *Nano Lett* (2020) 20(4):2246–56. doi: 10.1021/acs.nanolett.9b04094

51. Hong Y, Jooong H, Park L, Lee S, Shin YJ, Kim H, et al. STING Facilitates Nuclear Import of Herpesvirus Genome During Infection. *Proc Natl Acad Sci USA* (2021) 118(33):e2108631118. doi: 10.1073/pnas.2108631118

52. Chu TT, Tu X, Yang K, Wu J, Repa JJ, Yan N. Tonic Prime-Stress of Sting Signalling Mediates Niemann-Pick Disease Type C. *Nature* (2021) 596 (7873):575–5. doi: 10.1038/s41586-021-03762-2

53. Deribe YL, Dawson T, Dikker I. Post-Translational Modifications in Signal Integration. *Nat Struct Mol Biol* (2010) 17(6):666–72. doi: 10.1038/nsmb.1842

54. Zhou B, Yang Y, Li S, Wang YY, Li Y, Diao S, et al. The Adaptor Protein Mit-Ag Links Virus-Sensing Receptors to Irf3 Transcription Factor Activation. *Immunity* (2008) 29(4):358–50. doi: 10.1016/j.immuni.2008.09.003

55. Takahashi K, Niki T, Ogawa E, Fumika K, Nishikawa Y, Sawa M, et al. A Cell-Free Assay Implicates a Role of Sphingomyelin and Cholesterol in Sting Phosphorylation. *Sci Rep* (2021) 11(1):11996. doi: 10.1038/s41598-021-91562-z

56. Li J, Liu Q, Zhang X, Wu L, Wang X, Wu Y, et al. Phosphorylation of Sting to Prevent Sustained Innate Immune Signaling. *Sci China Life Sci* (2020) 63(5):786–96. doi: 10.1007/s11427-019-0877-4
Kang et al. Targeted PTMs of STING

85. Zhang J, Chen Y, Chen X, Zhang W, Zhao L, Weng L, et al. Deubiquitinase

89. Tian M, Liu W, Zhang Q, Huang Y, Li W, Wang W, et al. Mysm1 Represses

107. Fang R, Jiang Q, Guan Y, Gao P, Zhang R, Zhao Z, et al. Golgi Apparatus-

109. Soares da Costa D, Reis RL, Pashkuleva I. Sulfation of Glycosaminoglycans

118. PloS Pathog (2015) 11(6):e1005012. doi: 10.1371/journal.ppat.1004358

121. Sci Immunol (2019) 22(4):485

123. Proc Natl Acad Sci USA (2018) 115(33):E7768–E78. doi: 10.1073/pnas.1806239115

126. doi: 10.1038/jbm.2006335720

131. doi: 10.1084/jbm.2017a.486282

137. J Immunol (2019) 202(8):2397

142. J Biol Chem (2012) 287(47):35686

147. doi: 10.1038/s41586-018-0287-8

150. Vitturi DA, Chen CS, Woodcock SR, Salvatore SR, Bonacci G, Koenitzer JR, et al. Modulation of Nitro-Fatty Acid Signaling: Prostaglandin D2-Induced Downregulation of Inflammatory Signaling Molecules. J Biol Chem (2006) 281(47):E75713–E75718

157. Proc Natl Acad Sci USA (2018) 115(33):E7768–E78. doi: 10.1073/pnas.1806239115

162. Proc Natl Acad Sci USA (2018) 115(33):E7768–E78. doi: 10.1073/pnas.1806239115

167. Viggiano P, Petrino R, Pugliese F, Frandel MA, Colombo AP, Ceccatelli S, et al. Viral and cell death-induced activity of the Lemur CD114/CSF1R receptor. Sci Immunol (2017) 2(4):eaah0496. doi: 10.1126/sciadv.aah0496

172. Proc Natl Acad Sci USA (2018) 115(33):E7768–E78. doi: 10.1073/pnas.1806239115

177. Viggiano P, Petrino R, Pugliese F, Frandel MA, Colombo AP, Ceccatelli S, et al. Viral and cell death-induced activity of the Lemur CD114/CSF1R receptor. Sci Immunol (2017) 2(4):eaah0496. doi: 10.1126/sciadv.aah0496

182. Proc Natl Acad Sci USA (2018) 115(33):E7768–E78. doi: 10.1073/pnas.1806239115

187. Viggiano P, Petrino R, Pugliese F, Frandel MA, Colombo AP, Ceccatelli S, et al. Viral and cell death-induced activity of the Lemur CD114/CSF1R receptor. Sci Immunol (2017) 2(4):eaah0496. doi: 10.1126/sciadv.aah0496

192. Proc Natl Acad Sci USA (2018) 115(33):E7768–E78. doi: 10.1073/pnas.1806239115

197. Viggiano P, Petrino R, Pugliese F, Frandel MA, Colombo AP, Ceccatelli S, et al. Viral and cell death-induced activity of the Lemur CD114/CSF1R receptor. Sci Immunol (2017) 2(4):eaah0496. doi: 10.1126/sciadv.aah0496

202. Proc Natl Acad Sci USA (2018) 115(33):E7768–E78. doi: 10.1073/pnas.1806239115

207. Viggiano P, Petrino R, Pugliese F, Frandel MA, Colombo AP, Ceccatelli S, et al. Viral and cell death-induced activity of the Lemur CD114/CSF1R receptor. Sci Immunol (2017) 2(4):eaah0496. doi: 10.1126/sciadv.aah0496

212. Proc Natl Acad Sci USA (2018) 115(33):E7768–E78. doi: 10.1073/pnas.1806239115

217. Viggiano P, Petrino R, Pugliese F, Frandel MA, Colombo AP, Ceccatelli S, et al. Viral and cell death-induced activity of the Lemur CD114/CSF1R receptor. Sci Immunol (2017) 2(4):eaah0496. doi: 10.1126/sciadv.aah0496

222. Proc Natl Acad Sci USA (2018) 115(33):E7768–E78. doi: 10.1073/pnas.1806239115

Frontiers in Immunology | www.frontiersin.org 17 May 2022 | Volume 13 | Article 888147
Interferon Genes (Sting) Receptor Agonists. *J Med Chem* (2020) 63(1):260–82. doi: 10.1021/acs.jmedchem.9b01567

149. Basu S, Midha S, Banerjee M, Ghosh R, Pryde DC, Yadav DB, et al. The Discovery of Potent Small Molecule Cyclo Cysa Activators of Sting. *J Med Chem* (2022) 229:e114087. doi: 10.1021/acs.jmedchem.2114087

150. Pryde DC, Middya S, Banerjee M, Shrivastava R, Basu S, Ghosh R, et al. The Discovery of Potent Small Molecule Activators of Human Sting. *J Med Chem* (2021) 209:112869. doi: 10.1021/acs.jmedchem.20112869

151. Abraham J, Botto S, Mizuno N, Pryke K, Gall B, Boehm D, et al. Characterization of a Novel Compound That Stimulates Sting-Mediated Innate Immune Activity in an Allele-Specific Manner. *Front Immunol* (2020) 11:1430. doi: 10.3389/fimmu.2020.01430

152. Hou H, Yang R, Liu X, Wu X, Zhang S, Chen K, et al. Discovery of Triazolotriquinolinaline as Novel Sting Agonists Via Structure-Based Virtual Screening. *Bioorg Chem* (2020) 100:103958. doi: 10.1016/j.bioorg.2020.103958

153. Kimura Y, Negishi H, Matsuda A, Endo N, Hangai S, Inoue A, et al. Novel Chemical Compound Sincro With Dual Function in Sting-Type I Interferon and Tumor Cell Death Pathways. *Cancer Sci* (2018) 109(9):2687–96. doi: 10.1111/cas.13726

154. Khair S, Lucas-Hourami M, Nisole S, Smith N, Helynck O, Bourgine M, et al. Identification of a Small Molecule That Primes the Type I Interferon Response to Cytosolic DNA. *Sci Rep* (2017) 7(1):2561. doi: 10.1038/s41598-017-02776-z

155. Jung HR, Jo S, Jeon MJ, Lee H, Chu Y, Lee J, et al. Inhibition of Herpes Simplex Virus 1 by Cepharanthine (2021) 10(1):33. doi: 10.3390/biomedicines10010033

156. Cherney EC, Zhang L, Lo J, Huynh T, Wei D, Ahuja V, et al. Discovery of Chemical Compound Sincro With Dual Function in Sting-Type I Interferon Genes (Sting) Receptor Agonists. *Bioorg Chem* (2021) 193:105143. doi: 10.1016/j.antiviral.2021.105143

157. Hua D, Wu X. Small-Molecule Inhibitors Targeting Small Ubiquitin-Like Modifier Pathway for the Treatment of Cancers and Other Diseases. *Eur J Med Chem* (2022) 233:114227. doi: 10.1016/j.ejmech.2022.114227

158. Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING Agonists as Cancer Therapeutics. *Cancers* (Basel) (2021) 13(11):2695. doi: 10.3390/cancers13112695

159. Zhang X, Liu B, Tang L, Su Q, Hwang N, Sehgal M, et al. Discovery and Mechanistic Study of a Novel Human-Stimulator-Of-Interferon-Genes Agonist. *ACS Infect Dis* (2019) 5(7):1139–49. doi: 10.1021/acsinfecdis.9b00010

160. Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING Agonists as Cancer Therapeutics. *Cancers* (Basel) (2021) 13(11):2695. doi: 10.3390/cancers13112695

161. Sowers ML, Tang H, Tian B, Goldblum R, Midoro-Horiuti T, Zhang K. Bisphenol a Activates an Innate Viral Immune Response Pathway. *J Proteome Res* (2020) 19(2):664–34. doi: 10.1021/acs.jproteome.9b00548

162. Micel LN, Tandler JF, Smith PG, Eckhardt GS. Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies. *J Clin Oncol* (2013) 31(9):1231–8. doi: 10.1200/JCO.2012.44.0958

163. Senft D, Qi J, Ronai ZA. Ubiquitin Ligases in Oncogenic Transformation and Cancer Therapy. *Nat Rev Cancer* (2018) 18(2):69–88. doi: 10.1038/nrc.2017.105

164. Rape M. Ubiquitylation at the Crossroads of Development and Disease. *Nat Rev Mol Cell Biol* (2018) 19(1):59–70. doi: 10.1038/nrm.2017.83

165. Smith BAH, Bertozzi CR. The Clinical Impact of Glycobiology: Targeting Selectins, Siglecs and Mammalian Glycans. *Nat Rev Drug Discovery* (2021) 20(3):217–43. doi: 10.1038/s41573-020-00093-3

166. Ding C, Song Z, Shen A, Chen T, Zhang A. Small Molecules Targeting the Innate Immune Cgasstingb1 Signaling Pathway. *Acta Pharm Sin B* (2020) 10(12):2272–98. doi: 10.1016/j.apsb.2020.03.001

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2022 Kang, Wu, Liu, Wu, Zhao and Ren. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**